Patents by Inventor Michael Adler

Michael Adler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210058741
    Abstract: Systems and methods for improving safety of a multi-function portable personal communications device can include determining a first position of the personal communications device, after a predetermined time interval, determining a second position of the personal communications device, determining the distance between the first position and the second position, determining the time interval in which the personal communications device moved from the first position and the second position, calculating an average velocity of the personal communications device based on the first position, the second position and the time interval and, if the average velocity of the personal communication device exceeds a predetermined value, sending an alert or inhibiting a function of the personal communications device. Other systems and methods that improve safety are also disclosed.
    Type: Application
    Filed: April 6, 2020
    Publication date: February 25, 2021
    Inventors: Michael Adler, Russell Spiesser
  • Publication number: 20210054092
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 25, 2021
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10928236
    Abstract: A peristaltic dosing device for providing dosages of a fluid at a volume of less than one milliliter comprises: a flexible tube, a counter pressure element, a plurality of actors and a drive. The flexible tube is essentially straightly arranged along the counter pressure element thereby forming a longitudinal axis. The actors arranged parallel to each other along the longitudinal axis. They are moveable by the drive in relation to the flexible tube. The flexible tube is compressible between the actors and the counter pressure element by moving the actors. Each of the actors is independently and linearly moveable by the drive along an actuation axis essentially perpendicular to the longitudinal axis of the flexible tube from a home position in which the flexible tube is least compressed to an end position in which the flexible tube is compressed and sealed between the respective actor and the counter pressure element.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: February 23, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Michael Adler, Karoline Bechtold-Peters, Adeline Boillon, Anke Dorn, Joerg Luemkemann, Denis Luthringer, Hanns-Christian Mahler, Alexander Meyer
  • Patent number: 10752696
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: August 25, 2020
    Assignee: GENENTECH, INC.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10685129
    Abstract: A data processing system is provided with a data verification system that is configured to perform a validation check upon receipt of a request from a field device to transfer data to the data processing system. The data verification system is also configured to verify a permission of the field device to exchange data and to validate the data integrity. A data landing zone is provided for temporary storage of the data in the event that a validation check fails, so that data errors may be corrected.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: June 16, 2020
    Assignee: Siemens Aktiengesellschaft
    Inventors: Michael Adler, Klaus-Peter Hofmann
  • Patent number: 10587577
    Abstract: A gateway device disposed within a managed network may be communicatively coupled to a computational instance of a remote network management platform. The gateway device may also be configured with a list of network addresses assigned to the managed network, and configured to: receive network traffic from computing devices on the managed network, compare source addresses of the network traffic to the network addresses in the list, discard a first unit of the network traffic that has source addresses that are specified in the list, and for a second unit of the network traffic with source addresses that are not specified by the list, (i) encrypt, as a whole, payloads of each packet of the second unit of the network traffic, and (ii) transmit the encrypted packets from the gateway device to the computational instance. Network addresses in the list may be provided by a gateway controller device.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: March 10, 2020
    Assignee: ServiceNow, Inc.
    Inventors: Michael Adler, Anton Cheltsov
  • Patent number: 10538080
    Abstract: The invention pertains to a device for producing collections of sheet-like printed products from a supplied material strand, in which a switch feeds the product stream to a receiving cylinder via one of at least two collecting cylinders, as well as to a folding apparatus with such a collecting device.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: January 21, 2020
    Assignee: Kolbus GmbH & Co. KG
    Inventors: Michael Adler, Ronald Drabe, Jens Winter
  • Publication number: 20190367629
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 5, 2019
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20190356503
    Abstract: A method is provided for automatically creating data relating to an automation system, wherein a plurality of software agents is assigned to the automation system. The software agents are connected to the cloud via a gateway, wherein the cloud holds an agent configuration for each software agent. Data captured by at least some of the software agents and relate to at least one device, service, and/or data source of the automation system, which may be reached by the particular software agent, are received by the gateway. At least one software agent assigned to the automation system is configured by the gateway during processing of one or more agent configurations from the cloud and the captured data relating to at least one device, service, and/or data source may be reached by the particular software agent.
    Type: Application
    Filed: November 8, 2017
    Publication date: November 21, 2019
    Inventors: Michael ADLER, Klaus-Peter HOFMANN
  • Patent number: 10377831
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: August 13, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10300244
    Abstract: The invention is a catheter, which is formed from flexible material and has two basic configurations: An initial configuration, in which the catheter is supplied to the surgeon for insertion into the lumen of a patient, resembles a tension coil spring and a final configuration, which is an essentially linear configuration that is much longer and has a considerably smaller outer diameter than when it is in its initial configuration. The catheter is adapted to undergo a transformation from the initial configuration to the final configuration as it is pulled from its proximal end in order to withdraw it from the lumen of the patient.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: May 28, 2019
    Assignee: RENALSENSE LTD.
    Inventors: Michael Adler, Mor Grinstein, Jack Yehoshua Mantinband
  • Patent number: 10280227
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20190116459
    Abstract: Systems and methods for improving safety of a multi-function portable personal communications device can include determining a first position of the personal communications device, after a predetermined time interval, determining a second position of the personal communications device, determining the distance between the first position and the second position, determining the time interval in which the personal communications device moved from the first position and the second position, calculating an average velocity of the personal communications device based on the first position, the second position and the time interval and, if the average velocity of the personal communication device exceeds a predetermined value, sending an alert or inhibiting a function of the personal communications device. Other systems and methods that improve safety are also disclosed.
    Type: Application
    Filed: May 14, 2018
    Publication date: April 18, 2019
    Inventors: Michael Adler, Russell Spiesser
  • Publication number: 20190097973
    Abstract: A gateway device disposed within a managed network may be communicatively coupled to a computational instance of a remote network management platform. The gateway device may also be configured with a list of network addresses assigned to the managed network, and configured to: receive network traffic from computing devices on the managed network, compare source addresses of the network traffic to the network addresses in the list, discard a first unit of the network traffic that has source addresses that are specified in the list, and for a second unit of the network traffic with source addresses that are not specified by the list, (i) encrypt, as a whole, payloads of each packet of the second unit of the network traffic, and (ii) transmit the encrypted packets from the gateway device to the computational instance. Network addresses in the list may be provided by a gateway controller device.
    Type: Application
    Filed: September 27, 2017
    Publication date: March 28, 2019
    Inventors: Michael Adler, Anton Cheltsov
  • Publication number: 20180319157
    Abstract: The invention pertains to a device for producing collections of sheet-like printed products from a supplied material strand, in which a switch feeds the product stream to a receiving cylinder via one of at least two collecting cylinders, as well as to a folding apparatus with such a collecting device.
    Type: Application
    Filed: April 26, 2018
    Publication date: November 8, 2018
    Inventors: Michael ADLER, Ronald Drabe, Jens Winter
  • Publication number: 20180228895
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: April 10, 2018
    Publication date: August 16, 2018
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 9986385
    Abstract: Systems and methods for improving safety of a multi-function portable personal communications device can include determining a first position of the personal communications device, after a predetermined time interval, determining a second position of the personal communications device, determining the distance between the first position and the second position, determining the time interval in which the personal communications device moved from the first position and the second position, calculating an average velocity of the personal communications device based on the first position, the second position and the time interval and, if the average velocity of the personal communication device exceeds a predetermined value, sending an alert or inhibiting a function of the personal communications device. Other systems and methods that improve safety are also disclosed.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: May 29, 2018
    Assignee: WebSafety, Inc.
    Inventors: Michael Adler, Russell Spiesser
  • Patent number: 9968676
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: May 15, 2018
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20180077531
    Abstract: Systems and methods for improving safety of a multi-function portable personal communications device can include determining a first position of the personal communications device, after a predetermined time interval, determining a second position of the personal communications device, determining the distance between the first position and the second position, determining the time interval in which the personal communications device moved from the first position and the second position, calculating an average velocity of the personal communications device based on the first position, the second position and the time interval and, if the average velocity of the personal communication device exceeds a predetermined value, sending an alert or inhibiting a function of the personal communications device. Other systems and methods that improve safety are also disclosed.
    Type: Application
    Filed: May 22, 2017
    Publication date: March 15, 2018
    Inventors: Michael Adler, Russell Spiesser
  • Publication number: 20180060594
    Abstract: A data processing system is provided with a data verification system that is configured to perform a validation check upon receipt of a request from a field device to transfer data to the data processing system. The data verification system is also configured to verify a permission of the field device to exchange data and to validate the data integrity. A data landing zone is provided for temporary storage of the data in the event that a validation check fails, so that data errors may be corrected.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 1, 2018
    Inventors: Michael Adler, Klaus-Peter Hofmann